Mulberry Extracts Alleviate Aβ_{25–35}-Induced Injury and Change the Gene Expression Profile in PC12 Cells

Nan Song, 1,2 Hongpeng Yang, 3 Wei Pang, 1 Zhiwei Qie, 1 Hao Lu, 4 Long Tan, 1 Haiqiang Li, 1 Shoudan Sun, 1 Fuzhi Lian, 5 Chuan Qin, 2 and Yugang Jiang 1

1Department of Nutrition, Tianjin Institute of Health and Environmental Medicine, Tianjin 300050, China
2Comparative Medicine Center, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China
3Tianjin Agricultural College, 22 Jinjing Highway, Tianjin 300384, China
4Center for Disease Control and Prevention, PLA Chengdu Military Area Command, Chengdu 610021, China
5Department of Preventive Medicine, Hangzhou Normal University, Hangzhou 311121, China

Correspondence should be addressed to Fuzhi Lian; fuzhi.lian@hznu.edu.cn, Chuan Qin; qinchuan@pumc.edu.cn and Yugang Jiang; jyg1967@126.com

Received 9 July 2014; Revised 27 October 2014; Accepted 28 October 2014; Published 17 December 2014

1. Introduction

Alzheimer’s disease (AD) is the most common form of dementia in the elderly. AD, characterized by the progressive degeneration of cognition and memory, is correlated with the appearance of neurofibrillary tangles, senile plaques, and loss of neurons in the brain [1–4]. The processing of amyloid precursor protein (APP), a type I transmembrane glycoprotein, plays an important role in the development of AD [5, 6]. In the amyloidogenic pathway, cleavage of APP by β-secretase results in the release of a soluble, 110 kDa N-terminal fragment, sAPPβ, and a 12 kDa membrane-anchored C-terminal fragment, CTFβ. Subsequently, CTFβ is cleaved by γ-secretase and generates a 4 kDa Aβ peptide [7]. Aβ peptide is the major component of senile plaques and has been suggested to play a causal role in the development and progression of AD [8]. Aβ can trigger a cascade of pathogenic events such as culminating of neuronal apoptosis/death, dystrophy of neurites, excitoactivation of glutamate receptors, and induction of oxidation stress [9]. Aβ_{25–35}, a synthetic peptide corresponding to amino acids 25–35 in Aβ_{1–40} and Aβ_{1–42}, possesses the same β-sheet structure and exhibits large β-sheet fibrils [10, 11]. It retains most physical and biological properties of full length-Aβ, including its toxicity [12]. More importantly, Aβ_{25–35} is a particularly intractable...
peptide because it aggregates rapidly, unlike the full length-
\( \beta_\text{A} \), which requires aging for more than 1 week before it
aggregates and becomes toxic [13]. As such, it is often used for the in vitro study.

Anthocyanins are a group of naturally occurring phenolic
compounds that are responsible for the brilliant color of blue,
red, and purple of leaves, flowers, and fruits [14]. Because
of significant property of anthocyanin is antioxidant activity,
the neuroprotective effect of anthocyanin has received a lot
of attention in the field of nutrition research [4, 15]. Many
studies showed that effects of the antioxidant activity and
neuroprotection of anthocyanins in vitro. At the same time,
in vivo test also confirmed that anthocyanins can reduce
the injury area of cerebral ischemic damage in rat [16,
17]. Mulberries (Morus alba) have been used in traditional
oriental medicine throughout world and in particular in
China and contain high amounts of anthocyanins [14, 17,
18]. Zou et al. optimized the microwave-assisted extraction
(MAE) conditions of anthocyanins from mulberry using
response surface methodology (RSM). Under these condi-
tions, 54.72 mg anthocyanins were obtained from 1.0 g mul-
berry powder. Furthermore, 8 anthocyanins were identified
by high-performance liquid chromatography-electrospray
ionization-mass spectrometry (HPLC-ESI-MS) in mulberry
extract. Among them cyanidin-3-glucoside and cyanidin-3-
rutinoside are the major anthocyanins in mulberry [19, 20].
Studies showed that black-colored mulberry fruit extracts
contain the highest levels of anthocyanin, total phenolic, and
flavonoid as well as strongest antioxidant compared with
other colors of mulberry fruit extracts [8, 21]. Mulberry
fruits exhibit a variety of biological and physiological effects,
such as antithrombotic, antioxidant, antimicrobial activity,
anti-inflammation, and neuroprotection [4]. In recent years,
many papers have been published on the neuroprotective
effects of mulberry extracts (ME). Animal studies found
that mulberry fruits and their neuroprotective constituent—
cyanidin-3-O-β-D-glucopyranoside (C3G), isolated from the
mulberry fruits, can alleviate the cerebral ischemic injury and
aging-associated neuronal damage in vivo using a mouse-
brain-injury model with a transient middle cerebral artery
occlusion (MCAO) [10]. Shih et al. (2010) found that ME,
which are rich in phenolics and anthocyanins increased
the antioxidant enzymes activities (Glutathione peroxidase,
Catalase) and improved learning and memory ability in
senescence-accelerated mice (SAMP) [4]. In in vitro exper-
iments, anthocyanins in ME can inhibit \( \beta_\text{A} \) spontaneous
aggregation into oligomers and their neurotoxicity in human
neuronal SH-SY5Y cells and have neuroprotective effects on
the PC12 cells exposed to hydrogen peroxide and oxygen
glucose deprivation (OGD) [14, 19].

Yet few studies have used PC12 cells as \( \beta_\text{A} \)-induced
injury model to investigate cytoprotective and neuroprotec-
tive effects of ME in vitro. Furthermore, mechanisms that ME
pretreatment might inhibit development of AD have not been
elucidated clearly. To explore mechanisms involved, we use
\( \beta_\text{A} \) treated PC12 cell as an in vitro model to investigate
the role of ME and use the genomic techniques to quickly and
accurately quantify vast numbers of potential gene expression
changes after ME pretreatment. This study could thus have
a great nutrigenomics interest and bring new and important
light in the field of Alzheimer’s disease intervention.

2. Materials and Methods

2.1. Preparation of Black Mulberry Extracts. Mature mulberry
fruits (Morus nigra L.) were harvested from a local orchard
in turfan depression, Xinjiang Uygur Autonomous Region
in China, and purchased from Xinjiang Bencaoang Traditional
Chinese Herbal Decoction Pieces Co. Ltd. (Lot NO.: 10121805,
Tel.: +86 991 4639388). Mulberry extracts (ME), without
any of the amino acids and vitamins, were prepared in the
laboratory as described below. Blended fresh mulberry fruits
were extracted with 60% alcohol and dehydrated in a freeze
dryer (FD-I, USA) for 48 h in a vacuum freezer (−50°C).
Total anthocyanin content in black mulberry extracts was
6.8% (0.068 mg/mL) as measured using a full wavelength UV
spectrophotometer scanning (wavelength 282 nm). ME stock
solution was prepared by dissolving ME in Dulbecco’s mod-
ified Eagle’s medium (DMEM, Gibco, USA) (20 mg/mL) and
sterilized through a 0.22 μm filter. At the time of treatment,
ME stock solution was further diluted with culture medium
to a concentration of 200 μg/mL.

2.2. Cell Culture and Treatment. PC12 cell line (rat adrenal
pheochromocytoma, The Shanghai Institute of Biochemistry
and Cell Biology, SIBCB, China) was grown in high glucose
DMEM medium supplemented with 5% (v/v) fetal bovine
serum (FBS, HyClone, USA), 10% heat-inactivated horse
serum (HS, HyClone, USA), and 1% penicillin/streptomycin
(Sigma, USA) in a 5% CO2 incubator at 37°C and satu-
rated humidity. To induce neuronal differentiation, cells
were treated with 50 ng/mL of nerve growth factor (NGF,
Peprotech, USA). When cells were at about 80% confluence,
the medium was replaced with DMEM containing
1% FBS, 1% penicillin, and 1% streptomycin with NGF
(50 ng/mL). At the treatment, cells were divided into four
groups: (1) control group: no treatment, (2) \( \beta_\text{A} \) group:
cells were treated with 20 μmol/L \( \beta_\text{A} \) for 24 h, (3) ME
plus \( \beta_\text{A} \) group: cells were pretreated with 200 μg/mL ME
for 24 h, and then the medium was discarded and switched to
that containing 20 μmol/L \( \beta_\text{A} \) for another 24 h, and (4)
ME group: cells were treated with 200 μg/mL ME alone for
24 h [22]. Before the experiment, the \( \beta_\text{A} \) peptide solution
was incubated at 37°C for a week to produce the conformation
of fibril or aggregation before adding to PC12 cells.

2.3. Cell Viability. Cell viability was determined by MTT
assay. Briefly, PC12 cells were plated at a density of 1 × 10^4
cells/well in 96-well plates and treated with ME, \( \beta_\text{A} \), or
ME plus \( \beta_\text{A} \) at indicated concentration, respectively. At
the time of assay, cells were washed with PBS and incubated
with MTT reagent (5 g/L, 10% v/v, Sigma, USA) at 37°C for 4
hours. The resulting MTT formazan crystals were solubilized
by dimethylsulfoxide (DMSO, 150 μL) for 10 min at room
temperature. Optical density was measured at 570 nm using
a microtiter plate reader (uQuant). Results were expressed as
the percentage of MTT reduction as compared with control group.

2.4. RNA Isolation and cDNA Synthesis. Total RNA was extracted from various groups using Trizol reagent (Invitrogen, Life Technologies, USA) following instruction. The extracted RNA was further purified using RNeasy columns (QIAGEN RNeasy Mini Kit, Germany). The quantity and quality of the RNA was determined by Abs260/Abs280 ratio (≥1.80), Abs260/Abs230 ratio (≥1.50), and ethidium bromide fluorescence of RNA resolved in 1% agarose gels. cDNA was synthesized using an oligo dT-T7 promoter primer (Roche Molecular Biochemicals, Mannheim, Germany) and used as a template for in vitro transcription.

2.5. Microarray Analysis. Fluorescence labeled probes for oligo microarray analysis were prepared using Amino allyl Message Amp aRNA kit (Applied Biosystems, Foster City, CA, USA) as instructed. Labeled probes were hybridized to a Phalanx Rat OneArray containing 24358 rat specific probe sets (Phalanx Biotech Group, Inc., China Taiwan) at 50°C for 16 hrs. Slides were washed with 2 × SSC/0.2% SDS at 42°C for 5 min, 2 × SSC at 42°C for 5 min, 2 × SSC at 25°C for 5 min, and then ten times with 0.2 × SSC. Then spin dried slides were scanned using an Affymetrix Gene Array scanner (USA) and analyzed with GenePix 3.0 software (Axon Instruments, Union City, CA) to obtain gene expression ratios. Logged gene expression ratios were normalized by Lowess regression [23]. Rosetta Resolver System (Rosetta BioSoftware) was used for data preprocess and differential gene expression analysis. Cluster 3.0 and Tree View (http://rana.lbl.gov/EisenSoftware.htm) were employed to clustering analysis.

2.6. Reverse Transcription Polymerase Chain Reaction (RT-PCR). Total RNA was prepared as mentioned above using the same samples. PrimeScript RT Master Mix Perfect Real Time kit (Takara) was used to synthesize first strand cDNA as described by the manufacturer. Specific DNA sequences were amplified with a PCR mixture (TIANGEN Biotech, China) and resolved on a 2% agarose gel. PCR primers were indicated as follows: Apaf 1, 5’-ATGGTTATCCCTGTGGGAGAG-3’ (sense) and 5’-CAGCAGCAAGCAGCAGCAG-3’ (antisense); Bace 2, 5’-TTGGTGACGAGGACGATGA-3’ (sense) and 5’-CCTCCAACCCCTTGAGTGGTA-3’ (antisense); Plcb 4, 5’-GGGCCATTACTCCATCGTCTCC-3’ (sense), 5’-TACCATTGTCTTTCCGTTAGT-3’ (antisense); β-actin, 5’-CACCCGGGAGTACACATC-3’ (sense) and 5’-GCCATATTCCACACCCACC-3’ (antisense).

2.7. Statistics. Data are expressed as the mean ± standard deviation. Statistical analysis was performed by one-way analysis of variance (ANOVA) and post hoc Bonferroni/Dunn test. Values of P less than 0.05 were considered statistically significant.

Figure 1: Cytoprotective effects of mulberry extracts in Aβ25-35-induced PC12 cells. PC12 cells were pretreated with or without ME (200 μg/mL) for 24 h and exposed to Aβ25-35 (20 μmol/L) for 24 h. The cytotoxicity was measured by MTT assay. The viability of the untreated cells was set to 100%. The values represent mean (%) ± S.D. of each group (n = 8) of three different cultures. (#) Significantly different from the control group (P < 0.05). (*) Significantly different from the Aβ25-35 group (P < 0.05).

Table 1: Up- (≥2-fold) and down- (≤2-fold) regulation in gene expression in PC12 cells after exposure to Aβ25-35 or pretreatment with ME for 24 h.

| Comparison | Downregulated | Upregulated |
|------------|---------------|-------------|
| Aβ25-35 versus control | 16 | 5 |
| (ME + Aβ25-35) versus Aβ25-35 | 98 | 55 |

3. Results

3.1. Effect of ME on Viability in Aβ25-35 Treated PC12 Cells. Aβ25-35 treatment resulted in a significant decrease [(38.3 ± 6.9)%] in cell viability in PC12 cells as compared with the control group (P < 0.05, n = 8). ME treatment alone did not significantly affect cell viability; ME pretreatment inhibited Aβ25-35-induced cell death by (29.8 ± 8.7)% (Figure 1). The result shows that ME attenuated Aβ25-35-induced cell injury in PC12 cells.

3.2. Effect of ME on Gene Expression Profile of Aβ25-35 Treated PC12 Cells. Gene expression profile was analyzed by microarray method using 2-fold change (P < 0.05) as cut point. Of the 24358 genes on the chip, the expression levels of 5 genes (0.02%) were increased and those of 16 genes (0.07%) were decreased in cells treated with Aβ25-35 as compared with control. Pretreatment with ME resulted in increased expression of 55 genes (0.2%) and decreased expression of 98 genes (0.4%) as compared with Aβ25-35 group. Changes in gene expression reflect the influence of ME-supplement on the cells (Table 1).

3.3. Cluster Analysis and Gene Ontology (GO) Classification. For advanced data analysis, all biological replicates were pooled and calculated to identify differentially expressed genes based on the threshold of fold change and P value.
Table 2: Statistical results of GO classification in ME pretreatment group.

| Term                        | Count | Up | Upregulated                                      | Down | Downregulated          |
|-----------------------------|-------|----|--------------------------------------------------|------|-------------------------|
| Cell adhesion               | 11    | 3  | Pcdhb9, Igfls, Pcdh9                              | 8    | Ptprm, Dsg2, Pdpm, Trpm7, Icam2, Lmo7, Postn, Spp1 |
| Peptidase activity          | 12    | 4  | Acr, Em12, Cndp1, Xnpep3                          | 8    | Mmp10, Bace2, Serpinel, Serpinb2, Fgl2, Apat1, Mysml, Mmp12 |
| Regulation of angiogenesis  | 4     | 1  | Figf                                             | 3    | Col4a2, Ptprm, Serpinel |
| Cytokine activity           | 5     | 1  | IL33                                             | 4    | Il23a, Ccl2, Ccl27, Spp1 |
| Ion binding                 | 36    | 14 | Cndp1, Pcdhb9, Trim50, Cacnb2, Necab2, Vwde, Sdc, Tmem38b, Ng35, Cyp17a1, Pcdh9, Arg3, Xnpep3, Cyp4f1 | 22   |                        |
| Multicellular organism      | 9     | 4  | Acr, Avpr1a, Micalcl, Pcdhga1                     | 5    | Ccl2, Ccdn2, Acs14, Vgf, PrI8a2, Ccl4A2, Ccl2, Loc363458, Postn, Vgf, Mmp12, Mmp10, L23a, Adm, Wasl, Serpinb2, Sema3c, Spp1, Cld27, Serpinel, PrI8a2, Ptprm, Pdpn, Trpm7, Gas7, Col4a3bp, Serpin |
| Others                      | 31    | 9  | Matn3, Igfls, Ili33, Metrn, Figf, Avpr1a, Slc30a8, Sdc, Penk | 22   |                        |
| Total                       | 108   | 36 | 72                                               |      |                         |

Note: Upregulated means upregulated genes, Downregulated means downregulated genes.

The correlation of expression profiles between biological replicates and treatment conditions was demonstrated by unsupervised hierarchical clustering analysis. For this microarray project, the number of genes clustered was 144 (Figure 2). According to biological process ontology analysis, GO classification items enriched in the difference-expression genes were mainly related to cell adhesion, peptidase activity, cytokine activity, ion binding activity, and angiogenesis regulation in ME pretreatment group ($P < 0.05$) (Table 2, Figure 3).

3.4. Pathway Analysis and Verification. Based on NCBI database, the screened differentially expressed genes Apaf1, Bace2, and Plcb4 were enriched in the “Alzheimer’s disease-reference pathway” ($P < 0.01$) (Figure 4) and meanwhile significantly downregulated in Aβ25-35-injured PC12 cells after ME intervention as compared with Aβ25-35 group ($P < 0.05$) (Table 3). RT-PCR method was used to verify the changes of Apaf1, Bace2, and Plcb4 mRNA expression. Figure 5 showed that mRNA levels of Apaf1, Bace2, and Plcb4 were upregulated in Aβ25-35 treated PC12 cells as compared with control group ($P < 0.05$), increased by (82.6 ± 21.1)% (53.5 ± 13.0)%, and (31.9% ± 1.3)% respectively, while 200 μg/mL ME preincubation for 24h significantly inhibited Aβ25-35-induced upregulation of Apaf1, Bace2, and Plcb4 mRNA expression in PC12 cells ($P < 0.05$), decreased by (61.5 ± 13.2)% (33.9 ± 4.3)% and (43.1 ± 9.3)% respectively, which was consistent with the microarray analysis. These results indicated that ME pretreatment could substantially downregulate Apaf1, Bace2, and Plcb4 mRNA expression levels in Aβ25-35-injured PC12 cells.

4. Discussion

There is an increasing interest in the beneficial effects of nutritional antioxidants on health via the delay of aging and age-related diseases [24–29]. The observed protection may be the result of the antioxidant and anti-inflammatory properties of the polyphenolic compounds found in these fruits and vegetables [30]. Our previous studies found that pretreatment of PC12 cells with 200 μg/mL ME could almost completely reverse Aβ25-35-induced neuronal injury, counteract ROS formation, and inhibit apoptosis. The results suggested that ME could alleviate Aβ25-35-induced injury in PC12 cells, which might be associated with the antioxidative and antiapoptosis effects [22]. In this study, we further investigate the possible mechanisms involved.

To explore the molecular mechanisms of neuroprotective effect of ME, the transcription of 24,358 genes was analyzed by gene chips. Combined with bioinformatics analysis,
Figure 2: Hierarchical clustering of PC12 cells analyzed with the microarray chip. PC12 cells were pretreated with or without ME for 24 h and exposed to Aβ25-35 (20 μmol/L) for 24 h. Data are representative of three different experiments. Up- and downregulated genes are represented in red and green colors, respectively.
Upregulated gene after ME pretreatment as compared with Aβ25–35 group.

Downregulated gene after ME pretreatment as compared with Aβ25–35 group.

| GO Classification                  | Percentage |
|------------------------------------|------------|
| Cell adhesion                      | 25.0%      |
| Regulation of angiogenesis         | 11.1%      |
| Ion binding                        | 11.1%      |
| Others                             | 8.3%       |
| Peptidase activity                 | 30.6%      |
| Cytokine activity                  | 6.9%       |
| Multicellular organism reproduction | 38.9%      |

**Figure 3:** The results of GO classification in ME pretreatment group.

**Figure 4:** Screened differentially expressed genes were rich in Alzheimer’s disease-reference pathway (http://www.genome.jp/kegg-bin/show_pathway?rno05010). Note: The gene in red box represents downregulated expression after ME pretreatment in Alzheimer’s disease-reference pathway.
Figure 5: mRNA expression of Apaf1, Bace2, and Plcb4 genes measured by RT-PCR. Cells were pretreated with or without ME for 24h and exposed to Aβ25-35 (20 μmol/L) for 24h. (a) Typical mRNA bands of Apaf1, Bace2, Plcb4 and β-actin from control group, 200 μg/ml ME treatment alone group, pretreatment group with 200 μg/ml ME, and treatment group with Aβ25-35 alone. (b) Apaf1, Bace2 and Plcb4 mRNA levels were normalized to β-actin mRNA level and presented as relative value. The values represent mean ± S.D. of the each group (n = 6) of three independent experiments. (#) Significantly different from the control group (P < 0.05). (*) Significantly different from the Aβ25-35 group (P < 0.05).

The gene expression profiles in samples were significantly affected. Further analysis shows that in ME pretreatment group, the downregulated genes were mainly related to cell adhesion, cytokine activity, and angiogenesis regulation, and upregulated genes were mostly related to ion binding activity and multicellular organism reproduction. Based on NCBI database, the screened differentially expressed genes are Apaf1, Bace2, and Plcb4 were enriched in the “Alzheimer’s disease-reference pathway.” That is, these genes not only play an important role in the development of AD, but also their gene expression products are involved in apoptosis, Aβ formation, and cell or organelle membrane damage. We further validate that preincubation with ME significantly downregulated mRNA levels of Apaf1, Bace2, and Plcb4 in PC12 cells, suggesting that the bioactive components in ME can significantly inhibit cell apoptosis, Aβ formation, or membrane damage-associated gene expression.

Apoptotic protease-activating factor 1 (Apaf1), a tumor suppressor gene, is essential for regulation of mammalian development and induction of cell apoptosis [31–33]. The core of the mitochondria-dependent pathway is “apoptosome,” comprised by Apaf1, cytochrome C (Cyt.C), and dATP/ATP [34]. Furthermore, a series of apoptosis transduction cascade reactions in vivo act on Apaf1 firstly and then regulate apoptosis further [35]. In PC12 cells, Apaf1 is high expression in the peripheral blood leukocytes, spleen, fetal lung, kidney, and brain [36]. Changes in protein levels of Apaf1 determine cell proliferation or apoptosis. So the abnormal expression and function of Apaf1 is associated with the development of many human diseases [37]. The previous result found that ME preincubated cells can effectively reduce the rate of cell apoptosis [22]. The gene chip results and further validation found that Aβ25-35 increased expression of Apaf1 and ME pretreatment reversed the upregulation of Apaf1 expression induced by Aβ25-35. That is, ME could alleviate the apoptosis by the way of suppressing gene expression of Apaf1 in PC12 cells. It is further confirmed that Apaf1 is essential for the normal development of the brain [38] and the changes of transcription level of which may associate with the development of AD.

β-Secretase (β-site APP cleaving enzyme, BACE) is the rate limiting enzymatic activity in the production of the amyloid-β peptide (Aβ) and is thought to be involved in Alzheimer’s disease (AD) pathogenesis [39]. Though Bace2, the homologue of Bace1, is also expressed in the brain, its potential role in AD has not been clarified completely. However, Bace2 (Aspl, DRAP) also exhibits β-secretase-like activity [40, 41]. Transient expression of Bace2 in APP-expressing cells results in an increase in the levels of β-secretase derived cleavage products, sAPPβ and CTFβ, whose role has dispute in the pathogenesis of AD [7, 42]. So Bace2 maybe play critical role in the development of AD, because accumulation and deposition of Aβ fragments in brain induce Aβ-generated cascade process, which is an important step of AD pathologic processes. That is, by the way of inhibiting BACE2 activity, could directly decrease the level of Aβ. According to microarray analysis and PCR results, Bace2 mRNA in PC12 cells were obviously more...
overexpressed in Aβ25–35 group than those in the control group, while 200 μg/mL ME preincubated for 24 h could significantly inhibit Aβ25–35-induced upregulation of Bace2 mRNA expression. Therefore, we speculate that BACE2, not BACE1, as another therapeutic target, is expected to become a promising way to treat AD.

Translation products of Plcb4 gene are PLC-β 4, one of the isozymes of phospholipase C-β (PLC-β). Phospholipase C (PLC), as an important enzyme, is widespread in various cells, having species and cell specificity in the basic biochemical characteristics, function, and subcellular distribution [43, 44]. PLC is the phospholipid component of cellular membrane and also participates in the apoptosis signal transduction in various cells, such as neurons [45, 46]. Other studies have found that PLC is involved in the regulation of oxidative stress caused by oxidative glutamate toxicity induced neuronal cell death in immature cortical neurons and hippocampal neurons [47]. Our previous experimental results and other literature [20] found that ME pretreatment alleviated the damage of membrane structure of cells or organelles, especially preserved the mitochondrial membrane integrity and inhibited the decrease of mitochondrial membrane potential (see supplementary Figure in supplementary materials available online at http://dx.doi.org/10.1155/2014/150617). In the present research, we noted that Plcb4 mRNA in PC12 cells were obviously more overexpressed in Aβ25–35 group than those in the control group, which can be inhibited by ME preincubation. The results indicated that ME could inhibit apoptosis by the way of suppressing gene expression of Plcb4 in PC12 cells.

5. Conclusions

In summary, the results suggested that ME pretreatment could substantially alleviate the cell injury induced by Aβ25–35, which may be related to the antioxidative and antiapoptotic properties of ME (or anthocyanins). ME may negatively regulate the expression of Apaf1, Bace2, and Plcb4 genes, thereby delaying the development of AD.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Nan Song and Hongpeng Yang contributed equally to this work. Yugang Jiang, Chuan Qin, and Fuzhi Lian contributed equally to the supervision this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (30872098), the National Natural Science Foundation of Tianjin (09JCYBJC12900), and the Program for Zhejiang Leading Team of Science and Technology Innovation (2011R50021-17).

References

[1] K. A. Youdim, B. Shukitt-Hale, and J. A. Joseph, “Flavonoids and the brain: interactions at the blood-brain barrier and their physiological effects on the central nervous system,” Free Radical Biology and Medicine, vol. 37, no. 11, pp. 1683–1693, 2004.
[2] F. C. Lau, B. Shukitt-Hale, and J. A. Joseph, “The beneficial effects of fruit polyphenols on brain aging,” Neurobiology of Aging, vol. 26, supplement 1, pp. S128–S132, 2005.
[3] J.-H. Jang and Y.-J. Surh, “Protective effect of resveratrol on β-amloid-induced oxidative PC12 cell death,” Free Radical Biology and Medicine, vol. 34, no. 8, pp. 1100–1110, 2003.
[4] P.-H. Shih, Y.-C. Chan, J.-W. Liao, M.-F. Wang, and G.-C. Yen, “Antioxidant and cognitive promotion effects of anthocyanin-rich mulberry (Morus atropurpurea L.) on senescence-accelerated mice and prevention of Alzheimer’s disease,” The Journal of Nutritional Biochemistry, vol. 21, no. 7, pp. 598–605, 2010.
[5] J. Kang, H.-G. Lemaire, A. Unterbeck et al., “The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor,” Nature, vol. 325, no. 6106, pp. 733–736, 1987.
[6] D. J. Selkoe, “Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer’s disease,” Annual Review of Cell Biology, vol. 10, pp. 373–403, 1994.
[7] I. Hussain, D. J. Powell, D. R. Howlett et al., “Asp1 (BACE2) cleaves the amyloid precursor protein at the β-secretase site,” Molecular and Cellular Neuroscience, vol. 16, no. 5, pp. 609–619, 2000.
[8] S.-Y. Hong, W.-S. Jeong, and M. Jun, “Protective effects of the key compounds isolated from Corni fructus against β-amyloid-induced neurotoxicity in pc12 cells,” Molecules, vol. 17, no. 9, pp. 10831–10845, 2012.
[9] D. A. Butterfield, J. Drake, C. Pocernich, and A. Castegna, “Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid β-peptide,” Trends in Molecular Medicine, vol. 7, no. 12, pp. 548–554, 2001.
[10] Y. G. Kaminsky, M. W. Marlatt, M. A. Smith, and E. A. Kosenko, “Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: evidence for Aβ25–35,” Experimental Neurology, vol. 221, no. 1, pp. 26–37, 2010.
[11] R. Zhang, Z. Wang, P. A. Howson et al., “Smilagenin attenuates beta amyloid (25–35)-induced degeneration of neuronal cells via stimulating the gene expression of brain-derived neurotrophic factor,” Neuroscience, vol. 210, pp. 275–285, 2012.
[12] E. Aliaga, M. Silhol, N. Bonneau, T. Maurice, S. Arancibia, and L. Tapia-Arancibia, “Dual response of BDNF to subthalal concentrations of β-amyloid peptides in cultured cortical neurons,” Neurobiology of Disease, vol. 37, no. 1, pp. 208–217, 2010.
[13] E. Hughes, R. M. Burke, and A. J. Doig, “Inhibition of toxicity in the β-amyloid peptide fragment β(25–35) using N-methylated derivatives. A general strategy to prevent amyloid formation,” Journal of Biological Chemistry, vol. 275, no. 33, pp. 25109–25115, 2000.
[14] T. H. Kang, J. Y. Hur, H. B. Kim, J. H. Ryu, and S. Y. Kim, “Neuroprotective effects of the cyanidin-3-O-beta-d-glucopyranoside isolated from mulberry fruit against cerebral ischemia,” Neuroscience letters, vol. 391, no. 3, pp. 122–126, 2006.
[15] P. C. Bickford, T. Gould, L. Briederick et al., “Antioxidant-rich diets improve cerebellar physiology and motor learning in aged rats,” Brain Research, vol. 866, no. 1-2, pp. 211–217, 2000.

[16] Q. Du, J. Zheng, and Y. Xu, “Composition of anthocyanins in mulberry and their antioxidant activity,” Journal of Food Composition and Analysis, vol. 21, no. 5, pp. 390–395, 2008.

[17] P. Aramwit, N. Bang, and T. Srichana, “The properties and stability of anthocyanins in mulberry fruits,” Food Research International, vol. 43, no. 4, pp. 1093–1097, 2010.

[18] O. Yildiz, “Physicochemical and sensory properties of mulberry products: gümüşhanе pestil and kömе,” Turkish Journal of Agriculture and Forestry, vol. 37, no. 6, pp. 762–771, 2013.

[19] T. Zou, D. Wang, H. Guo et al., “Optimization of microwave-assisted extraction of anthocyanins from mulberry and identification of anthocyanins in extract using HPLC-ESI-MS,” Journal of Food Science, vol. 77, no. 1, pp. C46–C50, 2012.

[20] A. Tarozzi, F. Morroni, A. Merlicco et al., “The properties and stability of anthocyanins in mulberry fruit,” Food Research International, vol. 43, no. 4, pp. 1093–1097, 2010.

[21] T. Zou, D. Wang, H. Guo et al., “Optimization of microwave-assisted extraction of anthocyanins from mulberry and identification of anthocyanins in extract using HPLC-ESI-MS,” Journal of Food Science, vol. 77, no. 1, pp. C46–C50, 2012.

[22] N. Song, W. Pang, H. Yang et al., “Primary study on protective effect of mulberry extracts on Abeta25–35-induced PC12 cells injury,” Journal of Hygiene Research, vol. 41, no. 6, pp. 925–929, 2012.

[23] Y. H. Yang, S. Dudoit, P. Luu et al., “Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation,” Nucleic Acids Research, vol. 30, no. 4, article e15, 2002.

[24] R. L. Galli, B. Shukitt-Hale, K. A. Youdim, and J. A. Joseph, “Fruit polyphenolics and brain aging: nutritional interventions targeting age-related neuronal and behavioral deficits,” Annals of the New York Academy of Sciences, vol. 959, pp. 128–132, 2002.

[25] J. A. Joseph, B. Shukitt-Hale, and G. Casadesus, “Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds,” The American Journal of Clinical Nutrition, vol. 81, no. 1, pp. 313S–316S, 2005.

[26] J. A. Klein and S. L. Ackerman, “Oxidative stress, cell cycle, and neurodegeneration,” The Journal of Clinical Investigation, vol. 111, no. 6, pp. 785–793, 2003.

[27] J. Vaya and M. Aviram, “Nutritional antioxidants: mechanisms of action, analyses of activities and medical applications,” Current Medicinal Chemistry—Immunology, Endocrine & Metabolic Agents, vol. 1, no. 1, pp. 99–117, 2001.

[28] K. A. Youdim and J. A. Joseph, “A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects,” Free Radical Biology and Medicine, vol. 30, no. 6, pp. 583–594, 2001.

[29] K. A. Youdim, J. P. E. Spencer, H. Schroeter, and C. Rice-Evans, “Dietary flavonoids as potential neuroprotectants,” Biological Chemistry, vol. 383, no. 3-4, pp. 503–519, 2002.

[30] C. A. Rice-Evans and N. J. Miller, “Antioxidant activities of flavonoids as bioactive components of food,” Biochemical Society Transactions, vol. 24, no. 3, pp. 790–795, 1996.

[31] H. Yoshida, Y.-Y. Kong, R. Yoshida et al., “Apaf-1 is required for mitochondrial pathways of apoptosis and brain development,” Cell, vol. 94, no. 6, pp. 739–750, 1998.

[32] D. L. Vaux and A. Strasser, “The molecular biology of apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 6, pp. 2239–2244, 1996.

[33] H. Zou, W. J. Henzel, X. Liu, A. Lutschg, and X. Wang, “Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3,” Cell, vol. 90, no. 3, pp. 405–413, 1997.

[34] P. Li, D. Nijhawan, I. Budihardjo et al., “Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade,” Cell, vol. 91, no. 4, pp. 479–489, 1997.

[35] H. Zou, Y. Li, X. Liu, and X. Wang, “An APF-1-cytochrome C multimeric complex is a functional apoptosome that activates procaspase-9,” The Journal of Biological Chemistry, vol. 274, no. 17, pp. 11549–11556, 1999.

[36] C. Andrei, P. Margiocco, A. Poggi, L. V. Lotti, M. R. Torrisi, and A. Rubartelli, “Phospholipases C and A2 control lysosome-mediated IL-1β secretion: implications for inflammatory processes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9745–9750, 2004.

[37] M. S. Soengas, P. Capodici, D. Polsky et al., “Inactivation of the apoptosis effector Apaf-1 in malignant melanoma,” Nature, vol. 409, no. 6817, pp. 207–211, 2001.

[38] J. Tan, T. Town, Z. Suo et al., “Induction of CD40 on human endothelial cells by Alzheimer’s β-amyloid peptides,” Brain Research Bulletin, vol. 50, no. 2, pp. 143–148, 1999.

[39] R. R. Ahmed, C. J. Holler, R. L. Webb, F. Li, T. L. Beckett, and M. P. Murphy, “BACE1 and BACE2 enzymatic activities in Alzheimer’s disease,” Journal of Neurochemistry, vol. 112, no. 4, pp. 1045–1053, 2010.

[40] R. Yan, M. J. Blenkowski, M. E. Shuck et al., “Membrane-anchored aspartyl protease with Alzheimer’s disease β-secretase activity,” Nature, vol. 402, no. 6761, pp. 533–537, 1999.

[41] F. Acquati, M. Accarino, C. Nucci et al., “The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the Down critical region,” FEBS Letters, vol. 468, no. 1, pp. 59–64, 2000.

[42] B. D. Bennett, S. Babu-Khan, R. Loeloff et al., “Expression analysis of BACE2 in brain and peripheral tissues,” The Journal of Biological Chemistry, vol. 275, no. 27, pp. 20647–20651, 2000.

[43] M. Iturralle, J. Pardo, E. Lacasa et al., “Characterization of the lipolytic pathways that mediate free fatty acid release during Fas/CD95-induced apoptosis,” Apoptosis, vol. 10, no. 6, pp. 1369–1381, 2005.

[44] K. Xie, S. Huang, Z. Dong, S.-H. Juang, Y. Wang, and I. J. Fidler, “Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene,” Journal of the National Cancer Institute, vol. 89, no. 6, pp. 421–427, 1997.

[45] Y. Cheng, Q. Zhao, X. Liu, S. Araki, S. Zhang, and J. Miao, “Phosphatidylcholine-specific phospholipase C, p53 and ROS in the association of apoptosis and senescence in vascular endothelial cells,” FEBS Letters, vol. 580, no. 20, pp. 4911–4915, 2006.

[46] Y. Li, P. Maher, and D. Schubert, “Phosphatidylcholine-specific phospholipase C regulates glutamate-induced nerve cell death,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7748–7753, 1998.

[47] H. K. Tong, R. O. Hye, M. J. Sun et al., “Enhancement of neuroprotection of mulberry leaves (Morus alba L.) prepared by the anaerobic treatment against ischemic damage,” Biological and Pharmaceutical Bulletin, vol. 29, no. 2, pp. 270–274, 2006.